Cargando…

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force

Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the nee...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Kelly, Cost, Carrye, Davis, Ian, Glade-Bender, Julia, Grohar, Patrick, Houghton, Peter, Isakoff, Michael, Stewart, Elizabeth, Laack, Nadia, Yustein, Jason, Reed, Damon, Janeway, Katherine, Gorlick, Richard, Lessnick, Stephen, DuBois, Steven, Hingorani, Pooja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468706/
https://www.ncbi.nlm.nih.gov/pubmed/31031965
http://dx.doi.org/10.12688/f1000research.18139.1
_version_ 1783411495486357504
author Bailey, Kelly
Cost, Carrye
Davis, Ian
Glade-Bender, Julia
Grohar, Patrick
Houghton, Peter
Isakoff, Michael
Stewart, Elizabeth
Laack, Nadia
Yustein, Jason
Reed, Damon
Janeway, Katherine
Gorlick, Richard
Lessnick, Stephen
DuBois, Steven
Hingorani, Pooja
author_facet Bailey, Kelly
Cost, Carrye
Davis, Ian
Glade-Bender, Julia
Grohar, Patrick
Houghton, Peter
Isakoff, Michael
Stewart, Elizabeth
Laack, Nadia
Yustein, Jason
Reed, Damon
Janeway, Katherine
Gorlick, Richard
Lessnick, Stephen
DuBois, Steven
Hingorani, Pooja
author_sort Bailey, Kelly
collection PubMed
description Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children’s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group’s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.
format Online
Article
Text
id pubmed-6468706
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-64687062019-04-25 Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force Bailey, Kelly Cost, Carrye Davis, Ian Glade-Bender, Julia Grohar, Patrick Houghton, Peter Isakoff, Michael Stewart, Elizabeth Laack, Nadia Yustein, Jason Reed, Damon Janeway, Katherine Gorlick, Richard Lessnick, Stephen DuBois, Steven Hingorani, Pooja F1000Res Review Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children’s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group’s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established. F1000 Research Limited 2019-04-15 /pmc/articles/PMC6468706/ /pubmed/31031965 http://dx.doi.org/10.12688/f1000research.18139.1 Text en Copyright: © 2019 Bailey K et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Bailey, Kelly
Cost, Carrye
Davis, Ian
Glade-Bender, Julia
Grohar, Patrick
Houghton, Peter
Isakoff, Michael
Stewart, Elizabeth
Laack, Nadia
Yustein, Jason
Reed, Damon
Janeway, Katherine
Gorlick, Richard
Lessnick, Stephen
DuBois, Steven
Hingorani, Pooja
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
title Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
title_full Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
title_fullStr Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
title_full_unstemmed Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
title_short Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
title_sort emerging novel agents for patients with advanced ewing sarcoma: a report from the children’s oncology group (cog) new agents for ewing sarcoma task force
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468706/
https://www.ncbi.nlm.nih.gov/pubmed/31031965
http://dx.doi.org/10.12688/f1000research.18139.1
work_keys_str_mv AT baileykelly emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT costcarrye emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT davisian emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT gladebenderjulia emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT groharpatrick emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT houghtonpeter emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT isakoffmichael emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT stewartelizabeth emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT laacknadia emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT yusteinjason emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT reeddamon emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT janewaykatherine emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT gorlickrichard emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT lessnickstephen emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT duboissteven emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce
AT hingoranipooja emergingnovelagentsforpatientswithadvancedewingsarcomaareportfromthechildrensoncologygroupcognewagentsforewingsarcomataskforce